

Case Docket No. NDTCO.020A

Date: December 18, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Li et al.

Appl. No.

10/692,573

Filed

October 24, 2003

For

CATIONIC POLYMERS HAVING DEGRADABLE

CROSSLINKS

Examiner

Unknown

Group Art Unit:

Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 18, 2003

(Date)

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with twenty-four (24) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Registration No. 39,287

Attorney of Record

Customer No. 20,995

(619) 235-8550

51P Docket No.: NDTCO.020A

DEC 2 3 2003

INFORMATION DISCLOSURE STATEMENT

Applicant

Li et al.

App. No.

: 10/692,573

Filed

: October 24, 2003

For

CATIONIC POLYMERS HAVING

DEGRADABLE CROSSLINKS

Examiner

Unknown

Group Art Unit

Unknown

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing twenty-four (24) references that are also enclosed.

This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

12/18/2003

Joseph J. Mallon

Registration No. 39,287

Attorney of Record

Customer No. 20,995

(619) 235-8550

S:\DOCS\JOM\JOM-5569.DOC:121803

FORM PTO 1919

DEC 2 3 2003 H

INFORMATION

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY, DOCKET NO. NDTCO.020A

APPLICATION NO. 10/692,573

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT Li et al.

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE GROUP
October 24, 2003 Unknown

	U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
•						
	·					

	FOREIGN PATENT DOCUMENTS						
EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS SUE	SUBCLASS	TRANSLATION	
INITIAL						YES	NO
_			•				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
	1.	A. Kabanov, Pharm. Sci. & Tech. Today, 2 (9), 1999, 365-372				
	2.	B.M. Jeong, D.S. Lee, Y.H. Bae, S.W. Kim, Nature 388, 1997, 860–862				
	3.	B.M. Jeong, Y.K. Choi, Y.H. Bae, G. Zentner, S.W. Kim, J. Controlled Release 60, 1999, 109–114				
	4.	Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., and Behr, JP. Proc. Natl. Acad. Sci. USA 1995, 92, 7297-7301				
	5.	C-H. Ahn, S.Y. Chae, Y.H. Bae, S.W. Kim, J. Controlled Release, 80, 2002, 273-282				
	6.	Curiel, D. T., Agarwal, S., Wagner, E., Cotton, M. Proc. Natl. Acad. Sci. USA 1991, 88, 8850-8854				
	7.	Feng Liu and Leaf Huang, Journal of Controlled Release, Volume 78, 1-3, 2002, Pages 259-266				
	8.	Haensler, J., and Szoka, F. C., Jr. Bioconjugate Chem. 1993, 4, 372-379.				
_	9.	Henrik R. Ihre, Omayra L. Padilla De Jesus, Francis C. Szoka, Jr. and Jean M. J. Frechet, Bioconjugate Chem. 2002, 13, 443-452				
	10	JS. Remy, B. Abdallah, M. A. Zanta, O. Boussif, JP. Behr, B. Demeneix, Adv. Drug Delivery Rev. 30, 1998, 85-95				
	11	Jayanth Panyam and Vinod Labhasetwar, Advanced Drug Delivery Reviews, Volume 55, 3, 2003, Pages 329-347				

EXAMINER	DATE CONSIDERED
AFVANDAGO DALTAN IS OLTATION CONTOURS DE LA CONTOUR	

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

9	н	ᆮ		\sim	_	•

FORM PTO 449 DEC 2 3 2003 PADENCE INFORMATION DISCLOSURE STATEMENT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. NDTCO.020A

APPLICATION NO. 10/692,573

BY APPLICANT

APPLICANT Li et al.

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE October 24, 2003 **GROUP** Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
	12 Lim, Y-b., Kim, C-h., Kim K., Kim S. W., Park, J-s. J. Am., Chem., Soc. 2000, 122, 6524-6525					
•	13 M.X. Tang, F.C. Szoka, Gene Ther. 4, 1997, 823–832					
,	14 M.X. Tang, C.T. Redemann, F.C. Szoka; Bioconjugate Chem., 1996, 7, 703-714					
•	15 Miller, A. D. Angew. Chem. Int. Ed. 1998, 37, 1768-1785					
	16 Niren Murthy, Yi X. Thng, Stephany Schuck, Ming C. Xu, and Jean M. J. Frechet, J. AM. CHEM. SOC. 2002, 124, 12398-12399					
	17 Omayra L. Padilla De Jesus, Henrik R. Ihre, Lucie Gagne, Jean M. J. Frechet, and Francis C. Szoka, Jr. Bioconjugate Chem. 2002, 13, 453-461					
	18 R. Langer, N.A. Peppas, Science 263, 1994, 1715–1720					
	19 SO. Han, R.I. Mahato, Y.K. Sung, S.W. Kim, Mol. Ther. 2 (4) 2000, 302-317					
	20 Sara-Kaye Madsen and David J. Mooney, Pharmaceutical Science & Technology Today, Volume 3, 11, 2000, Pages 381-384					
	21 W. T. Godbey and A. G. Mikos, Journal of Controlled Release, Volume 72, 1-3, 2001, Pages 115-125.					
	22 Wagner, E., Cotton, M., Foisner, R., Birnstiel, M. L. Proc. Natl. Acad. Sci. USA 1991, 88, 4255-4259					
	23 Zabner, J., Fasbender, A. J., Moninger, T., Poellinger, K. A., and Welsh, M. J. (1995) J. Biol. Chem. 270, 18997-19007					
	Zhong Zhao, Jun Wang, Hai-Quan Mao and Kam W. Leong, Advanced Drug Delivery Reviews, Volume 55, 4, 2003, Pages 483-499					

S:\DOCS\JOM\JOM-5568.DOC:121803

EXAMINER

DATE CONSIDERED